| | Variables | Overall (N = 52,714) | Non-LM (N = 50,096) | LM (N = 2,618) |
| | Age | | Mean (SD) | 59.7 (12.3) | 59.6 (12.4) | 61.3 (11.0) |
| | Sex | | Female | 19,555 (37.1%) | 18,805 (37.5%) | 750 (28.6%) | | Male | 33,159 (62.9%) | 31,291 (62.5%) | 1,868 (71.4%) |
| | Laterality | | Left | 25,973 (48.8%) | 24,395 (48.7%) | 1,330 (50.3%) | | Right | 26,741 (50.3%) | 25,233 (50.4%) | 1,288 (48.7%) |
| | Race | | Asian | 3,625 (6.9%) | 3,408 (6.8%) | 217 (8.3%) | | Black | 5,701 (10.8%) | 5,523 (11.0%) | 178 (6.8%) | | Others | 1,031 (2.0%) | 992 (2.0%) | 39 (1.5%) | | White | 42,357 (80.4%) | 40,173 (80.2%) | 2,184 (83.4%) |
| | T_stage | | T1 | 35,124 (66.6%) | 34,842 (69.6%) | 282 (10.8%) | | T2 | 5,646 (10.7%) | 5,189 (10.4%) | 457 (17.5%) | | T3 | 10,959 (20.8%) | 9,465 (18.9%) | 1,494 (57.1%) | | T4 | 985 (1.9%) | 600 (1.2%) | 385 (14.7%) |
| | N_stage | | N0 | 50,392 (95.6%) | 48,646 (97.1%) | 1,746 (66.7%) | | N1 | 2,322 (4.4%) | 1,450 (2.9%) | 872 (33.3%) |
| | Tumor_size | | Mean (SD) | 53.6 (37.3) | 51.1 (34.7) | 101 (51.0) |
| | Histology | | 8120 | 182 (0.3%) | 147 (0.3%) | 35 (1.3%) | | 8255 | 1,344 (2.5%) | 1,219 (2.4%) | 125 (4.8%) | | 8260 | 6,029 (11.4%) | 5,931 (11.8%) | 98 (3.7%) | | 8310 | 35,878 (68.1%) | 34,176 (68.2%) | 1,702 (65.0%) | | 8312 | 5,736 (10.9%) | 5,351 (10.7%) | 385 (14.7%) | | 8317 | 2,210 (4.2%) | 2,190 (4.4%) | 20 (0.8%) | | Others | 1,335 (2.5%) | 1,082 (2.2%) | 253 (9.7%) |
| | Grade | | I | 5,923 (11.2%) | 5,862 (11.7%) | 61 (2.3%) | | II | 26,761 (50.8%) | 26,280 (52.5%) | 481 (18.4%) | | III | 15,484 (29.4%) | 14,401 (28.7%) | 1,083 (41.4%) | | IV | 4,546 (8.6%) | 3,553 (7.1%) | 993 (37.9%) |
|
|
LM, lung metastasis; 8120, transitional cell carcinoma; 8255, adenocarcinoma with mixed subtypes; 8260, papillary adenocarcinoma; 8310, clear cell adenocarcinoma; 8312, renal cell carcinoma; 8317, chromophobe renal carcinoma.
|
